Multipotent Adult Progenitor Cells (MAPCs)
Multipotent Adult Progenitor Cells (MAPCs) Uses, Dosage, Side Effects, Food Interaction and all others data.
Multipotent Adult Progenitor Cells (MAPCs) is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of Multipotent Adult Progenitor Cells (MAPCs) include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents. The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. Currently, Multipotent Adult Progenitor Cells (MAPCs) is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.
| Trade Name | Multipotent Adult Progenitor Cells (MAPCs) |
| Generic | MultiStem |
| MultiStem Other Names | Multipotent Adult Progenitor Cells (MAPCs) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How Multipotent Adult Progenitor Cells (MAPCs) works
Multipotent Adult Progenitor Cells (MAPCs)’s main focus is immunological, with MAPCs mainly acting by producing factors regulating the immune system, protecting damaged and injured cells, and also promoting tissue repair and healing. The MAPCs in Multipotent Adult Progenitor Cells (MAPCs) have the ability to express a range of therapeutically relevant proteins and factors with the potential to reduce inflammation, protect damaged or injured tissue, and enhance the formation of new blood vessels in areas of ischemic injury. Immune-wise, it acts to rebalance the immune system, with studies by the company showing that the therapy acts by reducing inflammation (with reduced inflammatory cytokine levels) and lessening activation and migration of the peripheral immune system to the site of injury. Additionally, this therapy potentially may have therapeutic effects through decreasing activation of the peripheral immune response to the initial injury which then results in reduction of inflammation and thereby means less secondary tissue damage and scarring while also allowing for accelerated repair processes. These cells have also been shown to lessen adverse results of inflammation while reparative immune cells are activated. In summary, there occurs simultaneous upregulation of reparative immune responses and downregulation of proinflammatory processes.
Outside of immunological applications, MAPCs are also being investigated for ischemic injury treatment and cardiovascular repair. Compared to MSCs, MAPCs have a stronger angiogenic protein release profile while also inducing more extensively developed vasculature in a study. Additionally, MAPCs also hold potential in being a functional cell source for orthopedic applications and to also promote tissue regeneration and healing. Evidence exists that MAPCs can differentiate into cells of mesenchymal lineages which includes bones, bone marrow, cartilage, fat, muscles, and tendon -- giving reason behind the investigating of MAPCs for treatment of bone and cartilage disease. MAPCs, compared to MSCs, also seem to have greater inclination for endothelial differentiation.
Innovators Monograph
You find simplified version here Multipotent Adult Progenitor Cells (MAPCs)
